Ibrutix

140 mg

Generic Name: Ibrutinib

Description:

Ibrutix is a brand name for Ibrutinib, an oral medication classified as a Bruton’s tyrosine kinase (BTK) inhibitor. It is primarily used in the treatment of various B-cell malignancies. Ibrutinib works by irreversibly binding to the BTK enzyme, which plays a crucial role in B-cell receptor signaling, thereby inhibiting the proliferation and survival of malignant B cells.

Indications:

Ibrutix (Ibrutinib) is commonly prescribed for:

• Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

• Mantle Cell Lymphoma (MCL)

• Waldenström's Macroglobulinemia (WM)

• Marginal Zone Lymphoma (MZL)

• Chronic Graft versus Host Disease (cGVHD)

Dosage Form:

• Oral capsules or tablets (commonly 140 mg, 280 mg, 420 mg, 560 mg depending on the indication)

Mechanism of Action:

Ibrutinib blocks the BTK enzyme, leading to the inhibition of malignant B-cell growth, reducing tumor progression.